Scarica l'app Stockscreener
14.97
1.45%
-0.22
Pre-mercato:
14.70
-0.27
-1.80%
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory Trial - Pulse 2.0
REPL SWOT Analysis: FDA Approval of TUDRIQEV Marks a Turning Point - GuruFocus
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - Stocktwits
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results - MarketBeat
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Form 8K Replimune Group Inc For: 7 August By Investing.com - Investing.com Nigeria
Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed - TradingView
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M - Stock Titan
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake - Stock Titan
Why Is Replimune (NASDAQ:REPL) Drawing Attention After Its Oncology Approval? - Kalkine Media
Replimune Group Releases Q1 2027 Financial Results - AlphaStreet
2026-08-14 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Group stock may move 5.6% on earnings release By Investing.com - Investing.com Nigeria
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - WBOC TV
Replimune Group stock may move 5.6% on earnings release - Investing.com
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - globenewswire.com
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV - scanx.trade
Form 8K Replimune Group Inc For: 14 August By Investing.com - Investing.com Australia
Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update - TradingView
Replimune Fiscal Q1 Net Loss Narrows - marketscreener.com
REPL: FDA approval of TUDRIQEV and new financing drive launch and extend cash runway for over a year - TradingView
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update - The Manila Times
Replimune Reports $69.8 Million First-Quarter Loss After TUDRIQEV FDA Approval - Quiver Quantitative
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - globenewswire.com
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - Morningstar
Replimune Group Stock Short Interest Rises to 57.95% - Moomoo
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock - MarketBeat
Emily Luisa Hill Sells 11,448 Shares of Replimune Group (NASDAQ:REPL) Stock - MarketBeat
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 39,341 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune group CEO Sushil Patel sells $510,252 in stock By Investing.com - Investing.com Nigeria
Replimune CFO Emily Hill sells $148,480 in shares for tax withholding - Investing.com Nigeria
Replimune group CEO Sushil Patel sells $510,252 in stock - Investing.com
Replimune Group Chief Executive Officer Sold Shares Worth Over $510K - TradingView
What happened at FDA? Replimune approval raises questions - The Cancer Letter
REPL Class Action ReminderRobbins LLP Reminds Investors - globenewswire.com
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - PR Newswire
Cantor Fitzgerald reiterates Replimune stock rating on launch potential By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Replimune stock rating on launch potential - Investing.com India
REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with - globenewswire.com
Replimune Group (NASDAQ:REPL) Sets New 12-Month HighHere's Why - MarketBeat
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):